Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPs-MTX for Malignant Pleural Effusion
NCT04131231Unknown
- Sponsor
- Peking Union Medical College
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of methotrexate in malignant pleural effusion (MPE) (2 arms), sponsored by Peking Union Medical College. Primary endpoint: Objective Response Rate at 4 weeks. Status: unknown.
02
Drugs
methotrexate
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT04131231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131231.